MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

Search

Quidel Corp

Fermé

28.58 1.71

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.32

Max

28.85

Chiffres clés

By Trading Economics

Employés

6,600

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+1.46% upside

Dividendes

By Dow Jones

Prochains Résultats

11 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

277M

1.9B

Ouverture précédente

26.87

Clôture précédente

28.58

Quidel Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 janv. 2026, 23:49 UTC

Actions en Tendance

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26 janv. 2026, 23:09 UTC

Principaux Mouvements du Marché

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26 janv. 2026, 23:52 UTC

Market Talk

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26 janv. 2026, 23:46 UTC

Market Talk

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26 janv. 2026, 23:37 UTC

Market Talk

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26 janv. 2026, 22:41 UTC

Market Talk

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26 janv. 2026, 22:26 UTC

Résultats

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26 janv. 2026, 22:26 UTC

Résultats

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26 janv. 2026, 22:25 UTC

Résultats

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26 janv. 2026, 22:25 UTC

Résultats

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26 janv. 2026, 22:25 UTC

Résultats

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26 janv. 2026, 22:24 UTC

Résultats

Karoon Energy 4Q Sales Revenue US$156.1 Million

26 janv. 2026, 22:23 UTC

Résultats

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26 janv. 2026, 22:23 UTC

Résultats

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26 janv. 2026, 22:23 UTC

Résultats

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26 janv. 2026, 22:22 UTC

Résultats

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26 janv. 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Fortescue: Alta Copper Shareholders Approve Takeover

26 janv. 2026, 22:02 UTC

Acquisitions, Fusions, Rachats

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26 janv. 2026, 21:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

26 janv. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 janv. 2026, 21:34 UTC

Résultats

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26 janv. 2026, 21:34 UTC

Résultats

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26 janv. 2026, 21:34 UTC

Résultats

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26 janv. 2026, 21:34 UTC

Résultats

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26 janv. 2026, 21:30 UTC

Résultats

Nucor 4Q Sales $7.69B >NUE

26 janv. 2026, 21:30 UTC

Résultats

Nucor 4Q Net $378M >NUE

26 janv. 2026, 21:30 UTC

Résultats

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26 janv. 2026, 21:30 UTC

Résultats

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26 janv. 2026, 21:30 UTC

Résultats

Nucor 4Q EPS $1.64 >NUE

Comparaison

Variation de prix

Quidel Corp prévision

Objectif de Prix

By TipRanks

1.46% hausse

Prévisions sur 12 Mois

Moyen 28.5 USD  1.46%

Haut 35 USD

Bas 22 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

3

Maintien

1

Vente

Éléments financiers

$

À Propos Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat